L3VLUP
ProSign in

PFE · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

PFEJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • PFE
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterPFEJNJ
Q3 202027 holders, $24.9bn30 holders, $26.2bn
Q4 202024 holders, $24.4bn32 holders, $26.6bn
Q1 202128 holders, $22.8bn31 holders, $25.3bn
Q2 202125 holders, $25.0bn37 holders, $25.6bn
Q3 202135 holders, $27.3bn40 holders, $24.1bn
Q4 202134 holders, $38.6bn33 holders, $25.2bn
Q1 202234 holders, $33.0bn35 holders, $28.2bn
Q2 202226 holders, $33.9bn33 holders, $26.9bn
Q3 202235 holders, $28.7bn36 holders, $25.4bn
Q4 202232 holders, $32.8bn35 holders, $27.6bn
Q1 202335 holders, $27.0bn42 holders, $24.5bn
Q2 202331 holders, $23.0bn38 holders, $25.0bn
Q3 202337 holders, $22.0bn37 holders, $18.9bn
Q4 202333 holders, $18.8bn31 holders, $19.0bn
Q1 202429 holders, $15.2bn32 holders, $19.7bn
Q2 202432 holders, $14.6bn35 holders, $20.4bn
Q3 202429 holders, $13.2bn28 holders, $22.3bn
Q4 202434 holders, $11.4bn37 holders, $20.4bn
Q1 202534 holders, $9.3bn32 holders, $20.5bn
Q2 202528 holders, $7.8bn31 holders, $18.4bn
Q3 202529 holders, $7.4bn32 holders, $23.7bn
Q4 202526 holders, $6.4bn29 holders, $27.8bn
Q1 202624 holders, $7.9bn34 holders, $35.6bn
Q2 202622 holders, $5.2bn33 holders, $39.1bn
PFE

Pfizer Inc

Holders
28
Reported value
$7.8bn
Buyers
16
Sellers
14

Breadth +2 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
JNJ

Johnson & Johnson

Holders
31
Reported value
$18.4bn
Buyers
15
Sellers
16

Breadth -1 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2025

Among the 40 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only PFE (9)

Balyasny Asset Management LLC, Capital World Investors, Citadel Advisors LLC, Jane Street Group LLC, Squarepoint Ops LLC, Starboard Value LP, Susquehanna International Group LLP, Voloridge Investment Management LLC, Walleye Capital LLC

Only JNJ (12)

Capital Research Global Investors, Fidelity (FMR LLC), Janus Henderson Group Ltd, Markel Group Inc, Marshall Wace LLP, Point72 Asset Management LP, Quantbot Technologies LP, Renaissance Technologies LLC, Two Sigma Advisers LP, Two Sigma Investments LP, Verition Fund Management LLC, Winton Group Ltd

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →